Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Similarity of MAB-22 vs Prolia in Healthy Males
NCT06310824Phase 1Completed
- Sponsor
- Xentria
- Start
- Jun 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of INTP23 in osteoporosis (3 arms), sponsored by Xentria. Primary endpoints: Area under the concentration-time curve from time 0 extrapolated to infinity and Maximum observed serum concentration. Started Jun 2024; status: completed.
02
Drugs
INTP23
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06310824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310824.